Back to top

oncology-screening: Archive

Zacks Equity Research

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.

CTMXNegative Net Change SPROPositive Net Change KRYSNegative Net Change CSTLNegative Net Change

Zacks Equity Research

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.

GILDNegative Net Change CTMXNegative Net Change SPROPositive Net Change CSTLNegative Net Change

Zacks Equity Research

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

BMYNegative Net Change PFENegative Net Change GILDNegative Net Change CADLNegative Net Change

Zacks Equity Research

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change CRDFNegative Net Change

Zacks Equity Research

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change TARANegative Net Change